The efficacy of tissue factor -603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.
Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study regarding the association of TF gene -603A/G and +5466A>G polymorphisms with VTE in malignancy. Materials and Me-thods: The study consists of two groups: cancer patients with VTE were included as Group 1 (n = 46); Group 2 comprises 196 cancer patients without VTE. Restriction fragment length polymorphism method was used for the detection of polymorphisms of TF -603A/G in the 5՛upstream region and TF 5466A/G in intron 2. FVL, PT G20210A and MTHFR C677T polymorphisms were determined by using commercially available Light Cycler kits. The genotype and allele frequencies between the groups were compared using χ2 or Fisher exact test, if appropriate.


RESULTS
No differences were observed in the distribution of TF gene -603A/G genotype frequencies between the groups. Although a slightly increased incidence of +5466GA genotype was in Group 1 (17.4% vs 11.2%), it did not achieve statistical significance. The prevalence of FVL was significantly greater in Group 1 compared with Group 2 (41.3% vs 4.1%, p < 0.05). Difference in frequency of 677TT+CT (MTHFR) + 5466GG (TF) genotypes combination was found in women of two investigated Groups (p < 0.05). No differences were also in genotypes and allele frequencies of MTHFR C677T and PT G20210A between two Groups (p > 0.05).


CONCLUSIONS
The present study did not show significant association of TF gene -603A/G and +5466A>G polymorphisms with VTE in malignancy, however, further larger studies including different ethnic population are needed to confirm our findings.
Department of General Surgery, Surgical Oncology Unit, Ankara University Faculty of Medicine, Cebeci Kampus, Dikimevi, Ankara 06590, Turkey.
A
A
Eroğlu
Department of Genetics, Yildirim Beyazit University Faculty of Medicine, Bilkent, Ankara 06800, Turkey.
G G
GG
Ceylan
Department of Genetics, Yildirim Beyazit University Faculty of Medicine, Bilkent, Ankara 06800, Turkey.
E
E
Ozturk
Department of General Surgery &amp; Surgical Oncology, Ankara University Medical School, Ankara 06260, Turkey.
A
A
Yalcin
Department of Medical Oncology,Yildirim Beyazit University School of Medicine, Atatürk Education and Research Hospital, Ankara 06800, Turkey.
B
B
Yalcin
Hacettepe University Faculty of Science, Department of Statistics, Beytepe, Ankara 06800, Turkey.
D
D
Karasoy
D005165:Factor V / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000235:genetics; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D013925:Thromboplastin / Q000235:genetics*; D054556:Venous Thromboembolism / Q000209:etiology* / Q000235:genetics*
C095381:factor V Leiden; D005165:Factor V; D013925:Thromboplastin; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2)